Drug Developer Must Face Suboxone Product-Hopping Claims

Law360, New York (October 30, 2017, 9:25 PM EDT) -- A Pennsylvania federal judge found that sufficient evidence supports allegations that drug delivery developer MonoSol Rx LLC engaged in an anti-competitive scheme to delay generic versions of an opioid addiction treatment, rejecting the company's bid to toss the suit brought by more than 40 states Monday.

Judge Mitchell Goldberg determined that MonoSol exhibited plausible intent under the Sherman Antitrust Act to establish an illegal monopoly on the market for Suboxone in conspiring with Indivior Inc. to prolong its market exclusivity on the drug, which has earned it an estimated $2 billion. The states claims have also survived Indivior's previous motion to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!